AstraZeneca warns of limited vaccine supplies to Europe

Credit: CC0 Public Domain

British pharmaceutical firm AstraZeneca warned Friday that supplies of its coronavirus vaccine to Europe will be “lower than originally anticipated” due to reduced production at a manufacturing site.

The jab it developed with the University of Oxford in England is already being rolled out across the UK, but the European Union has not yet approved its use. It is expected to make a decision by January 29.

AstraZeneca said in a statement that if EU approval is granted, the “initial volumes will be lower than anticipated,” although the start would not be delayed.

The company blamed “reduced yields at a manufacturing site within our European supply chain,” without giving details.

It said it would in any case supply the EU with “millions of doses” while ramping up production in February and March.

Stefan De Keersmaecker, European Commission spokesperson for health, told AFP that AstraZeneca had confirmed the change to its delivery schedule at a meeting on Friday and added: “We are working to find out more.”

It was not clear how many doses AstraZeneca had initially been expected to deliver to the 27-country bloc.

The firm said last year it had agreed with the European Commission to supply up to 400 million doses.

The EU has said it has secured contracts for more than two billion doses, more than enough for its of 450 million, provided that all the vaccines are approved.

The Oxford-AstraZeneca is considered key to the global vaccination effort because it is cheaper to produce and can be stored at fridge temperature.

The EU has so far has approved vaccines made by Pfizer-BioNTech and Moderna.

While the vaccines have been developed and approved at record-breaking speed, deliveries of the first batches have been smaller than many EU members had hoped.

Pfizer has announced delays in shipments of its vaccine in the next few weeks owing to works at its main processing plant in Belgium.

EU countries have administered more than five million doses to citizens to date. The aim is to inoculate 70 percent of adults by the end of August.


Follow the latest news on the coronavirus (COVID-19) outbreak


© 2021 AFP

Citation:
AstraZeneca warns of limited vaccine supplies to Europe (2021, January 22)
retrieved 22 January 2021
from https://medicalxpress.com/news/2021-01-astrazeneca-limited-vaccine-europe.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Health News

Aromatherapy spray linked to US deaths faces recall

This undated photo provided by Walmart and the U.S. Centers for Disease Control and Prevention shows a bottle of Better Homes & Gardens aromatherapy lavender & chamomile essential oil and semiprecious stone-infused room spray. The Consumer Product Safety Commission and Walmart issued a recall Friday, Oct. 22. 2021, for 3,900 bottles of the spray. Credit: Walmart/CDC […]

Read More
Health News

mRNA vaccine more effective booster to ChAdOx1 nCoV-19

(HealthDay)—Use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination, according to a study published online Oct. 17 in The Lancet Regional Health: Europe. Peter Nordström, M.D., Ph.D., from Umeå University in Sweden, and colleagues examined the effectiveness of heterologous prime-boost COVID-19 vaccination among individuals in […]

Read More
Health News

Moving monoclonal antibody treatments for COVID from hospital to home

(HealthDay)—Antibody infusions help keep high-risk COVID-19 patients out of the hospital, but getting the therapy can be a challenge. One U.S. health system has found a creative way to address the problem: home infusions administered by paramedics. They delivered antibody infusions to 144 COVID-19 patients in their homes over three months earlier this year. Most—about […]

Read More